Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 321-325

  Abou Alfa, Ghassan K ^a   Chapman, Paul B ^a   Feilchenfeldt, Jonas ^a   Brennan, Murray F ^a   Capanu, Marinela ^a   Gansukh, Bolorsukh ^a   Jacobs, Gria ^a   Levin, Adrah ^a   Neville, Deirdre ^a   Kelsen, David P ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adjuvant; K ras; pancreatic cancer; vaccine

Indexed keywords

CANCER VACCINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; K RAS PROTEIN; PEPTIDE VACCINE; RAS12D PEPTIDE; RAS12R PEPTIDE; RAS12V PEPTIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; INJECTION SITE ERYTHEMA; MALE; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; SURVIVAL TIME; TUMOR IMMUNITY; VOMITING;

ADENOCARCINOMA; ADULT; AGED; CANCER VACCINES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDIES; FEMALE; GENES, RAS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; MUTATION; PANCREATECTOMY; PANCREATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958244310     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e84b1f     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985- 1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7. (Pubitemid 29307735)
3. Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701-706.
4. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
5. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer. 2005;5:459-467. (Pubitemid 40791488)
6. Ueda S, Fukamachi K, Matsuoka Y, et al. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis. 2006;27:2497-2510. (Pubitemid 44884109)
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321: 1801-1806.
8. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545-554. (Pubitemid 24058210)
9. Eggerding FA. Analysis of oncogenic ras gene mutations by coupled amplification and oligonucleotide ligation. Proc Am Assoc Cancer Res. 1995;36: 209.
10. Fenton RG, Taub DD, Kwak LW, et al. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst. 1993;85:1294-1302. (Pubitemid 23249721)
11. Yao TJ, Begg CB, Livingston PO. Optimal sample size for a series of pilot trials of new agents. Biometrics. 1996;52:992-1001. (Pubitemid 26296076)
12. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet. 1995;346:1399-1400.
13. Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol. 2005;23:5099-5107. (Pubitemid 46224018)
14. Buanes T, Bernhardt S, Lislerud K, et al. RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti-tumor response and long term survival. J Clin Oncol. 2007;25:4543.
15. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer. 2006;95:1474-1482. (Pubitemid 44863349)
16. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14:3060-3069.
17. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony- stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005;23:720-731. (Pubitemid 46224171)
18. Kaufman HL, Kim-Schulze S, Manson K, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007;5:60.
19. Maki RG, Livingston PO, Lewis JJ, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2007;52:1964-1972. (Pubitemid 47024649)
20. Laheru D, Biedrzycki B, Thomas AM, et al. Development of a cytokinemodified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Med. 2005;103:299-327.
21. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocytemacrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-156. (Pubitemid 32063491)
22. Laheru D, Yeo C, Biedrzycki B, et al. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. J Clin Oncol. 2007;25(suppl 18):AA3010.
23. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277. (Pubitemid 46143304)
24. Neoptolemos J, Büchler M, Stocken DD, et al. A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/ folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2009;27(suppl 18). Abstract LBA4505.